Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/25/2026

1. SPY
2. AKAM
3. COST
4. META
5. ZS
6. NVDA
7. DRI
8. ULS
9. AWK
10. USO

Go back to Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
(NASDAQ: RLYB) Delayed: 16.62 +0.01 (0.06%)
Previous Close $16.61    52 Week High $ 
Open $16.80    52 Week Low $ 
Day High $17.07    P/E N/A 
Day Low $16.62    EPS $ 
Volume 7,027